PacBio price target lowered to $1.50 from $2 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on PacBio (PACB) to $1.50 from $2 and keeps an Equal Weight rating on the shares. The shares ran up in early June following upbeat commentary at a conference, which creates a relatively higher bar for second half of 2025 numbers, the analyst tells investors in a research note. This makes Barclays more cautious given the “tough” National Institutes of Health funding environment.